These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 21044773)
1. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Lopez OL; Schwam E; Cummings J; Gauthier S; Jones R; Wilkinson D; Waldemar G; Zhang R; Schindler R Alzheimers Dement; 2010 Nov; 6(6):431-9. PubMed ID: 21044773 [TBL] [Abstract][Full Text] [Related]
2. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866 [TBL] [Abstract][Full Text] [Related]
3. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Jones RW; Schwam E; Wilkinson D; Waldemar G; Feldman HH; Zhang R; Albert K; Schindler R Alzheimer Dis Assoc Disord; 2009; 23(4):357-64. PubMed ID: 19561444 [TBL] [Abstract][Full Text] [Related]
4. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
5. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Winblad B; Black SE; Homma A; Schwam EM; Moline M; Xu Y; Perdomo CA; Swartz J; Albert K Curr Med Res Opin; 2009 Nov; 25(11):2577-87. PubMed ID: 19735164 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM; Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715 [TBL] [Abstract][Full Text] [Related]
7. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ; Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448 [TBL] [Abstract][Full Text] [Related]
10. For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? Ames D; Kaduszkiewicz H; van den Bussche H; Zimmermann T; Birks J; Ashby D Int Psychogeriatr; 2008 Apr; 20(2):259-92. PubMed ID: 18252031 [No Abstract] [Full Text] [Related]
11. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693 [TBL] [Abstract][Full Text] [Related]
12. Navigating patients and caregivers through the course of Alzheimer's disease. Aupperle PM J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846 [TBL] [Abstract][Full Text] [Related]
13. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594 [TBL] [Abstract][Full Text] [Related]
15. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. Passmore AP; Bayer AJ; Steinhagen-Thiessen E J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632 [TBL] [Abstract][Full Text] [Related]
16. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866 [TBL] [Abstract][Full Text] [Related]
17. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment? Stiles MM; Martin S; Persons RK J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040 [No Abstract] [Full Text] [Related]
18. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669 [TBL] [Abstract][Full Text] [Related]
19. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974 [TBL] [Abstract][Full Text] [Related]